Thiolated chitosan nanoparticles: transfection study in the Caco-2 differentiated cell culture - PubMed (original) (raw)
Thiolated chitosan nanoparticles: transfection study in the Caco-2 differentiated cell culture
Ronny Martien et al. Nanotechnology. 2008.
Abstract
The aim of this study was to monitor the expression of secreted protein in differentiated Caco-2 cells after transfection with nanoparticles, in order to improve gene delivery. Based on unmodified chitosan and thiolated chitosan conjugates, nanoparticles with the gene reporter pSEAP (recombinant Secreted Alkaline Phosphatase) were generated at pH 4.0. Transfection studies of thiolated chitosan in Caco-2 cells during the exponential growth phase and differentiation growth phase of the cells led to a 5.0-fold and 2.0-fold increase in protein expression when compared to unmodified chitosan nanoparticles. The mean particle size for both unmodified chitosan and cross-linked thiolated chitosan nanoparticles is 212.2 ± 86 and 113.6 ± 40 nm, respectively. The zeta potential of nanoparticles was determined to be 7.9 ± 0.38 mV for unmodified chitosan nanoparticles and 4.3 ± 0.74 mV for cross-linked thiolated chitosan nanoparticles. Red blood cell lysis evaluation was used to evaluate the membrane damaging properties of unmodified and thiolated chitosan nanoparticles and led to 4.61 ± 0.36% and 2.29 ± 0.25% lysis, respectively. Additionally, cross-linked thiolated chitosan nanoparticles were found to exhibit higher stability toward degradation in gastric juices. Furthermore the reversible effect of thiolated chitosan on barrier properties was monitored by measuring the transepithelial electrical resistance (TEER) and is supported by immunohistochemical staining for the tight junction protein claudin. According to these results cross-linked thiolated chitosan nanoparticles have the potential to be used as a non-viral vector system for gene therapy.
Similar articles
- Chitosan-thioglycolic acid conjugate: an alternative carrier for oral nonviral gene delivery?
Martien R, Loretz B, Thaler M, Majzoob S, Bernkop-Schnürch A. Martien R, et al. J Biomed Mater Res A. 2007 Jul;82(1):1-9. doi: 10.1002/jbm.a.31135. J Biomed Mater Res A. 2007. PMID: 17265441 - Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Shahnaz G, Vetter A, Barthelmes J, Rahmat D, Laffleur F, Iqbal J, Perera G, Schlocker W, Dünnhaput S, Augustijns P, Bernkop-Schnürch A. Shahnaz G, et al. Int J Pharm. 2012 May 30;428(1-2):164-70. doi: 10.1016/j.ijpharm.2012.02.044. Epub 2012 Mar 5. Int J Pharm. 2012. PMID: 22421322 - The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery.
Millotti G, Perera G, Vigl C, Pickl K, Sinner FM, Bernkop-Schnürch A. Millotti G, et al. Drug Deliv. 2011 Apr;18(3):190-7. doi: 10.3109/10717544.2010.522611. Epub 2010 Nov 2. Drug Deliv. 2011. PMID: 21039318 - Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.
Sadeghi AM, Dorkoosh FA, Avadi MR, Weinhold M, Bayat A, Delie F, Gurny R, Larijani B, Rafiee-Tehrani M, Junginger HE. Sadeghi AM, et al. Eur J Pharm Biopharm. 2008 Sep;70(1):270-8. doi: 10.1016/j.ejpb.2008.03.004. Epub 2008 Mar 12. Eur J Pharm Biopharm. 2008. PMID: 18492606 - Thiolated chitosans.
Bernkop-Schnürch A, Hornof M, Guggi D. Bernkop-Schnürch A, et al. Eur J Pharm Biopharm. 2004 Jan;57(1):9-17. doi: 10.1016/s0939-6411(03)00147-4. Eur J Pharm Biopharm. 2004. PMID: 14729077 Review.
Cited by
- Caco-2 Cells for Measuring Intestinal Cholesterol Transport - Possibilities and Limitations.
Hiebl V, Schachner D, Ladurner A, Heiss EH, Stangl H, Dirsch VM. Hiebl V, et al. Biol Proced Online. 2020 Apr 11;22:7. doi: 10.1186/s12575-020-00120-w. eCollection 2020. Biol Proced Online. 2020. PMID: 32308567 Free PMC article. - Nanoparticles of Thiolated Xanthan Gum for the Oral Delivery of Miconazole Nitrate: In Vitro and In Vivo Evaluation.
Namazi NI, Alrbyawi H, Alanezi AA, Almuqati AF, Shams A, Ali HSM. Namazi NI, et al. Pharmaceutics. 2024 Feb 4;16(2):225. doi: 10.3390/pharmaceutics16020225. Pharmaceutics. 2024. PMID: 38399279 Free PMC article. - Degradability of chitosan micro/nanoparticles for pulmonary drug delivery.
Islam N, Dmour I, Taha MO. Islam N, et al. Heliyon. 2019 May 15;5(5):e01684. doi: 10.1016/j.heliyon.2019.e01684. eCollection 2019 May. Heliyon. 2019. PMID: 31193324 Free PMC article. Review. - MicroRNA-155-5p Diminishes in Vitro Ovarian Cancer Cell Viability by Targeting HIF1α Expression.
Ysrafil Y, Astuti I, Anwar SL, Martien R, Sumadi FAN, Wardhana T, Haryana SM. Ysrafil Y, et al. Adv Pharm Bull. 2020 Sep;10(4):630-637. doi: 10.34172/apb.2020.076. Epub 2020 Aug 9. Adv Pharm Bull. 2020. PMID: 33062603 Free PMC article. - Gastrointestinal Tract Stabilized Protein Delivery Using Disulfide Thermostable Exoshell System.
Sadeghi S, Vallerinteavide Mavelli G, Vaidya SS, Drum CL. Sadeghi S, et al. Int J Mol Sci. 2022 Aug 30;23(17):9856. doi: 10.3390/ijms23179856. Int J Mol Sci. 2022. PMID: 36077259 Free PMC article.
LinkOut - more resources
Full Text Sources